• Order within –h –m
  • Free shipping on orders over $250
  • Free Bacteriostatic Water 30ml with $500+ purchase
  • Every batch tested by an independent lab

PT-141 (Bremelanotide) 10mg

$48.00

CAS: 189691-06-3 · MW: 1025.2 Da · Purity: ≥99% by reverse-phase HPLC · Format: 10 mg powder · Identity: ESI-MS confirmed

46 in stock

In Stock

COA verified · View report

Purchase & earn 48 points.
Quantity pricingSave up to 20%
QuantityPrice / vialSavingsAdd
1 vial$48.00–
3 vials$45.60Save 5%
5 vials$43.20Save 10%
10 vials Best value$38.40Save 20%

Purity Guarantee: Every vial is backed by independent third-party domestic lab and Janoshik analytical verification.

  • Third-Party TestedIdentity + purity, every batch. Secondary testing on rotation.
  • Janoshik Analytical3rd party domestic labs verified
  • Same-Day ShippingOrder by 2 PM PST, ships today
  • Ships from California2 Day UPS Air. Free shipping over $250

Research use only. Not for human consumption. Sold to qualified researchers.

Accepted:
  • Visa
  • Mastercard
  • Amex
  • Discover
  • Apple Pay
  • Zelle
  • ACH
  • Bitcoin, 10% off

PT-141 is a peptide that acts on the melanocortin receptors, a receptor family studied in pigmentation and central-nervous-system signalling research. It is structurally related to an earlier melanocortin (pigmentation) peptide and was redirected toward melanocortin signalling in the nervous system. Each vial contains 10 mg of freeze-dried powder, supplied as a reference compound for melanocortin-receptor research.

Description

Structure & Identity

PT-141 is a cyclic heptapeptide, meaning its seven-amino-acid chain is joined into a ring rather than left as a straight line. That ring shape locks the molecule into a stable form and is a big part of why it holds onto its melanocortin receptor targets. It is a close chemical relative of the melanocortin agonist family, but its cyclic structure sets it apart from the linear peptides in that group.

Research Background

PT-141 research centers on the melanocortin receptors, particularly MC3R and MC4R, and on what happens when those receptors are switched on.

  • Melanocortin agonist. PT-141 is characterized as a non-selective agonist across melanocortin receptors [PMID: 31429064].
  • Receptor system. The central melanocortin system it engages is an active target in metabolic and neurological research [PMID: 37365323].
  • Cellular model. Recent work examined bremelanotide’s melanocortin-receptor activity in a cultured-cell viability assay [PMID: 39197897].
  • Compound overview. Review profiles summarize its melanocortin pharmacology [PMID: 34436837].

These are laboratory research contexts. The material carries no approved use and is intended only for that kind of study.

Specifications

Attribute Value
Chemical name Bremelanotide (PT-141)
Also Known As Bremelanotide, PT-141
CAS number 189691-06-3
Molecular formula C50H68N14O10
Molecular weight 1025.2 g/mol
Structure Cyclic heptapeptide
Purity ≥99% by reverse-phase HPLC
Length Cyclic 7 amino acids
Identity Confirmed by ESI mass spectrometry
Physical form Lyophilized powder
Appearance White to off-white solid
Quantity 10 mg per vial
Storage -20°C, protected from light
Solubility Soluble in bacteriostatic or sterile water
Classification Research use only

Storage & Handling

Keep the sealed vial frozen at -20°C and protected from light until you need it. After preparation, the solution should be refrigerated at 2-8°C and used in research within roughly two weeks. Bringing a cold vial up to room temperature before opening limits condensation, and minimizing freeze-thaw cycles helps the cyclic peptide stay intact.

Storage and Handling Guide

Quality Assurance

PT-141 is produced under research-grade manufacturing controls and passes independent testing before it is released. Purity comes from reverse-phase HPLC and identity from mass spectrometry, performed by third-party laboratories, including Janoshik Analytical and domestic US labs, rather than in-house only. The certificate of analysis is matched to each batch, so its purity and identity figures apply to your specific vial.

Quality & Testing

Frequently Asked Questions

What is PT-141?

PT-141, or Bremelanotide, is a cyclic seven-amino-acid peptide that activates melanocortin receptors. It is studied in laboratory research on melanocortin signaling and is supplied for research use only.

Is PT-141 the same as bremelanotide?

Yes. “PT-141” is the research name and “Bremelanotide” is the chemical/drug name for the same molecule.

Which receptors does PT-141 act on?

It acts as a non-selective agonist across several melanocortin receptors, with reported activity at MC1R, MC3R, and MC4R. That broad action is what makes it useful for studying the melanocortin system.

How is PT-141 related to Melanotan 2?

Both come from melanocortin research and both are agonists at melanocortin receptors, but they are different molecules with different structures. PT-141 is cyclic; Melanotan 2 is a different melanocortin analog.

Is PT-141 FDA approved?

The bremelanotide molecule is approved as a drug in a specific clinical context, but the material sold here is a research-use-only reference peptide, not for human or veterinary use.

What is PT-141’s molecular weight?

Its molecular formula is C50H68N14O10 and its molecular weight is about 1025.2 g/mol, with CAS number 189691-06-3.

How should PT-141 be stored?

Store the dry powder at -20°C, protected from light. After reconstitution for research, keep it at 2-8°C and use within about two weeks.

How is the quality of this PT-141 verified?

It is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch comes with its own certificate of analysis.

References

  1. Bremelanotide: Melanocortin-receptor pharmacology PMID: 31429064.
  2. Central melanocortin-system receptor pharmacology. 2023. PMID: 37365323.
  3. Melanocortin Receptor Agonist Bremelanotide in Glioblastoma. 2024. PMID: 39197897.

Additional information

Weight 0.03 kg

Published research

Selected literature

Peer-reviewed studies that describe the research context for this compound. Listed for reference, not as a claim about use.

  • Melanocortin Agonist ProfileCharacterization of bremelanotide's receptor activity.PubMed 31429064
  • Central Melanocortin SystemThe melanocortin pathway as a research target.PubMed 37365323
  • Cultured-Cell ModelMelanocortin-receptor activity in a cell-viability assay.PubMed 39197897
  • Compound OverviewA review profile of bremelanotide. PubMed 34436837

Related products